UBS Group
PLYX

UBS Group’s Polaryx Therapeutics Inc PLYX Stock Holding History

UBS Group’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41K Sell
1,283
-12,196
-90% -$47.9K ﹤0.01% 9194
2026
Q1 		$102K Buy
+13,479
New +$87.1K ﹤0.01% 6992

Other funds holding PLYX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

UBS Group's PLYX Position: Q2 2026 in Review

UBS Group reduced its Polaryx Therapeutics Inc (PLYX) stake by 90% in Q2 2026, selling an estimated $47.9K and leaving 1,283 shares worth $3.41K. The position accounts for ﹤0.01% of the portfolio, ranked #9194.

UBS Group first reported a position in PLYX in Q1 2026 and has held it in 2 quarters since. The position peaked at $102K in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

  • UBS Group held 1,283 shares of Polaryx Therapeutics Inc worth $3.41K as of Q2 2026.
  • UBS Group sold 12,196 Polaryx Therapeutics Inc shares in Q2 2026, an estimated $47.9K.
  • Polaryx Therapeutics Inc made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9194 holding.
  • UBS Group first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 2 quarters since.
  • UBS Group's Polaryx Therapeutics Inc position peaked at $102K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.